ATE349213T1 - Nasale pharmazeutische zusammensetzung von piribedil - Google Patents

Nasale pharmazeutische zusammensetzung von piribedil

Info

Publication number: ATE349213T1
Authority: AT; Austria
Prior art keywords: piribedil; pharmaceutical composition; nasal pharmaceutical; nasal; composition
Prior art date: 2003-07-17

Application number

AT04767691T

Other languages

English (en)

Inventor

Herve Rolland

Patrick Wuthrich

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-17

Filing date

2004-07-16

Publication date

2007-01-15

2004-07-16 Application filed by Servier Lab filed Critical Servier Lab

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE349213T1 publication Critical patent/ATE349213T1/de

Links

OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical group C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229960004310 piribedil Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04767691T 2003-07-17 2004-07-16 Nasale pharmazeutische zusammensetzung von piribedil ATE349213T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0308712A FR2857594B1 (fr)	2003-07-17	2003-07-17	Composition pharmaceutique pour l'administration par voie nasale de piribedil

Publications (1)

Publication Number	Publication Date
ATE349213T1 true ATE349213T1 (de)	2007-01-15

Family

ID=33548200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04767691T ATE349213T1 (de)	2003-07-17	2004-07-16	Nasale pharmazeutische zusammensetzung von piribedil

Country Status (29)

Country	Link
US (1)	US20060204449A1 (de)
EP (1)	EP1653963B1 (de)
JP (1)	JP2007516947A (de)
KR (1)	KR100807480B1 (de)
CN (1)	CN100540004C (de)
AR (1)	AR046808A1 (de)
AT (1)	ATE349213T1 (de)
AU (1)	AU2004258714A1 (de)
BR (1)	BRPI0412681A (de)
CA (1)	CA2532631C (de)
CY (1)	CY1106013T1 (de)
DE (1)	DE602004003955T2 (de)
DK (1)	DK1653963T3 (de)
EA (1)	EA011041B1 (de)
ES (1)	ES2279435T3 (de)
FR (1)	FR2857594B1 (de)
GE (1)	GEP20074259B (de)
HR (1)	HRP20070081T5 (de)
MA (1)	MA27864A1 (de)
MX (1)	MXPA06000641A (de)
MY (1)	MY137747A (de)
NO (1)	NO332776B1 (de)
NZ (1)	NZ544460A (de)
PL (1)	PL1653963T3 (de)
PT (1)	PT1653963E (de)
SI (1)	SI1653963T1 (de)
UA (1)	UA85193C2 (de)
WO (1)	WO2005009442A1 (de)
ZA (1)	ZA200600240B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102105169B (zh) *	2008-06-06	2014-09-10	图必制药公司	用于治疗帕金森病的药物组合物
US20160022572A1 (en) *	2013-03-13	2016-01-28	N To B Ltd.	Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
IT201800005117A1 (it) *	2018-05-07	2019-11-07		Acqua irradiata con energie elettromagnetiche per uso terapeutico

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69434304T2 (de) *	1993-03-26	2005-12-29	Merkus, Franciscus Wilhelmus H.M.	Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
BE1007402A5 (nl) *	1993-03-26	1995-06-06	Adir	Nasale farmaceutische preparaten met progestagene stof.
FR2710265B1 (fr) *	1993-09-22	1995-10-20	Adir	Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
FR2710268B1 (fr) *	1993-09-22	1995-10-20	Adir	Utilisation de beta-cyclodextrines partiellement méthylées comme promoteurs d'absorption dans la préparation de compositions pharmaceutiques pour l'administration transcutanée de principes actifs.
FR2742989B1 (fr) *	1995-12-29	1998-01-23	Adir	Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
JP2001518923A (ja) *	1997-03-26	2001-10-16	ダブリュエイチエムマーカス，フランシスカス	鼻腔用メラトニン組成物
EP0900567A3 (de) *	1997-09-05	2001-05-02	Pfizer Products Inc.	Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie
US20020002175A1 (en) *	2000-09-19	2002-01-03	Charanjit Behl	Nasal delivery of apomorphine in combination with glycol derivatives
US20040028613A1 (en) *	2001-06-25	2004-02-12	Nastech Pharmaceutical Company Inc	Dopamine agonist formulations for enhanced central nervous system delivery
FR2827516B1 (fr) *	2001-07-19	2003-09-19	Servier Lab	Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone

2003
- 2003-07-17 FR FR0308712A patent/FR2857594B1/fr not_active Expired - Fee Related
2004
- 2004-07-15 MY MYPI20042838A patent/MY137747A/en unknown
- 2004-07-15 AR ARP040102489A patent/AR046808A1/es unknown
- 2004-07-16 AU AU2004258714A patent/AU2004258714A1/en not_active Abandoned
- 2004-07-16 ES ES04767691T patent/ES2279435T3/es not_active Expired - Lifetime
- 2004-07-16 MX MXPA06000641A patent/MXPA06000641A/es active IP Right Grant
- 2004-07-16 EA EA200600172A patent/EA011041B1/ru not_active IP Right Cessation
- 2004-07-16 US US10/564,139 patent/US20060204449A1/en not_active Abandoned
- 2004-07-16 UA UAA200601630A patent/UA85193C2/ru unknown
- 2004-07-16 NZ NZ544460A patent/NZ544460A/en not_active IP Right Cessation
- 2004-07-16 CN CNB2004800197495A patent/CN100540004C/zh not_active Expired - Fee Related
- 2004-07-16 SI SI200430163T patent/SI1653963T1/sl unknown
- 2004-07-16 PT PT04767691T patent/PT1653963E/pt unknown
- 2004-07-16 WO PCT/FR2004/001867 patent/WO2005009442A1/fr not_active Ceased
- 2004-07-16 DK DK04767691T patent/DK1653963T3/da active
- 2004-07-16 DE DE602004003955T patent/DE602004003955T2/de not_active Expired - Lifetime
- 2004-07-16 PL PL04767691T patent/PL1653963T3/pl unknown
- 2004-07-16 BR BRPI0412681-5A patent/BRPI0412681A/pt not_active IP Right Cessation
- 2004-07-16 ZA ZA200600240A patent/ZA200600240B/en unknown
- 2004-07-16 AT AT04767691T patent/ATE349213T1/de active
- 2004-07-16 HR HR20070081T patent/HRP20070081T5/xx unknown
- 2004-07-16 EP EP04767691A patent/EP1653963B1/de not_active Expired - Lifetime
- 2004-07-16 CA CA2532631A patent/CA2532631C/fr not_active Expired - Fee Related
- 2004-07-16 KR KR1020067001141A patent/KR100807480B1/ko not_active Expired - Fee Related
- 2004-07-16 GE GEAP20049239A patent/GEP20074259B/en unknown
- 2004-07-16 JP JP2006519966A patent/JP2007516947A/ja active Pending
2005
- 2005-12-27 MA MA28688A patent/MA27864A1/fr unknown
2006
- 2006-02-16 NO NO20060743A patent/NO332776B1/no not_active IP Right Cessation
2007
- 2007-02-13 CY CY20071100190T patent/CY1106013T1/el unknown

Also Published As

Publication number	Publication date
EP1653963B1 (de)	2006-12-27
KR100807480B1 (ko)	2008-02-25
DE602004003955T2 (de)	2007-12-06
FR2857594A1 (fr)	2005-01-21
MXPA06000641A (es)	2006-03-30
HK1094153A1 (zh)	2007-03-23
WO2005009442A1 (fr)	2005-02-03
DE602004003955D1 (de)	2007-02-08
CY1106013T1 (el)	2011-04-06
NO20060743L (no)	2006-02-16
GEP20074259B (en)	2007-12-10
JP2007516947A (ja)	2007-06-28
NO332776B1 (no)	2013-01-14
UA85193C2 (ru)	2009-01-12
CA2532631C (fr)	2011-01-04
CN1819828A (zh)	2006-08-16
PT1653963E (pt)	2007-02-28
CA2532631A1 (fr)	2005-02-03
SI1653963T1 (sl)	2007-04-30
CN100540004C (zh)	2009-09-16
BRPI0412681A (pt)	2006-10-03
FR2857594B1 (fr)	2005-09-16
AU2004258714A1 (en)	2005-02-03
HRP20070081T5 (hr)	2007-08-31
ES2279435T3 (es)	2007-08-16
PL1653963T3 (pl)	2007-02-28
HRP20070081T3 (hr)	2007-04-30
KR20060031689A (ko)	2006-04-12
DK1653963T3 (da)	2007-04-10
EA011041B1 (ru)	2008-12-30
ZA200600240B (en)	2007-03-28
AR046808A1 (es)	2005-12-28
NZ544460A (en)	2008-04-30
MY137747A (en)	2009-03-31
EP1653963A1 (de)	2006-05-10
MA27864A1 (fr)	2006-04-03
EA200600172A1 (ru)	2006-06-30
US20060204449A1 (en)	2006-09-14

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1653963

Country of ref document: EP

Publication	Publication Date	Title
DE60201988D1 (de)	2004-12-23	Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CY2017048I2 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
ATE380544T1 (de)	2007-12-15	Umhüllte feste darreichungsform
DE60201859D1 (de)	2004-12-16	Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60333294D1 (de)	2010-08-19	Kontrollierte verabreichung von arzneien
EP1513825A4 (de)	2011-01-05	Antituberkulöses arzneimittel: zusammensetzungen und verfahren
EP1603593A4 (de)	2007-08-01	Pharmazeutische zusammensetzung
CY2018005I2 (el)	2018-06-27	Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
DE60213592D1 (de)	2006-09-14	Flüssige pharmazeutische zusammensetzung
EP1425019A4 (de)	2004-11-17	Pharmazeutische zusammensetzung
DE60312049D1 (de)	2007-04-05	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ATE309789T1 (de)	2005-12-15	Darreichungsform von ibuprofen-natrium
EP1689419A4 (de)	2009-01-14	Pharmazeutische zusammensetzungen mit niedrigen dosen von desmopressin
ATE477814T1 (de)	2010-09-15	Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ITMI20021684A1 (it)	2004-01-29	Composizione farmaceutica di peptide nasale
PL361518A1 (pl)	2004-02-09	Zastosowanie substancji oraz kompozycja farmaceutyczna
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE507831T1 (de)	2011-05-15	Melatonin enthaltende pharmazeutische formulierung
NO20054662D0 (no)	2005-10-11	Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
DE112004001618D2 (de)	2006-05-11	Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
ATE349213T1 (de)	2007-01-15	Nasale pharmazeutische zusammensetzung von piribedil
DE502004009045D1 (de)	2009-04-09	Injizierbare darreichungsform von flupirtin
ATE439354T1 (de)	2009-08-15	Pharmazeutische salze von reboxetin
ATE443512T1 (de)	2009-10-15	Pharmazeutische zusammensetzung von piperazinderivaten
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung